Sign in
CompletedNo phase

Pharmacokinetics of Voriconazole in Adult ECMO Patients

Key facts

Who runs it
University Hospitals, Leicester
Where
United Kingdom1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
32 people enrolled
Started
10 Aug 2021
Ended
31 May 2025
Type of study
Observational
Treatments tested
  • 5 blood samples
  • Determination of CYP2C19 genotype
Record updated
6 January 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Adults aged ≥18 years
  • Admitted to ICU on ECMO support
  • Positive influenza or SARS-CoV-2 PCR from nasal, throat swab, BAL or other respiratory specimen
  • Positive invasive aspergillosis infection (positive Aspergillus species culture from respiratory specimen or positive serum galactomannan) or strong clinical suspicion of invasive aspergillosis infection based on symptoms, CT, CXR

Who cannot take part

  • Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant's ability to participate in the trial
  • No participants < 18 years of age
  • Not requiring ECMO support
  • No positive influenza or SARS-CoV-2 results

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Given the high burden of fungal co-infection in patients admitted to ICU and improved outcomes with prompt anti-fungal treatment, it is of vital importance that the doses of anti-fungal are optimum to improve the dismal outcome of influenza/Covid-19 Associated Pulmonary Aspergillosis.

Read full original descriptionShow less

Due to the reported difficulties in dosing appropriately in ECMO patients, a prospective observational study is required to accurately evaluate the pharmacokinetics of voriconazole in patients supported on ECMO. This is to ensure that the dose of voriconazole is optimised to improve efficacy and reduce toxicity.

The group in the trial

  • Voriconazole administration to adult patients with suspected fungal disease, receiving ECMO support

    Adult (\>18 years) patients with severe influenza / Covid-19 supported on ECMO and with confirmed or suspected aspergillosis infection.

    Treatment: 5 blood samples and Determination of CYP2C19 genotype

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
An Observational Pharmacokinetic Study of Intravenous Voriconazole Used for Treatment of Invasive Aspergillosis in Adult Patients With Severe Influenza / COVID-19 Supported With Extra-corporeal Membrane Oxygenation (ECMO)
Publications
Record updated
6 January 2026